June 2013
Volume 54, Issue 15
ARVO Annual Meeting Abstract  |   June 2013
AAV-mediated treatment of retinal degeneration in the Nrf2 knockout mouse
Author Affiliations & Notes
  • Katharine Liang
    Gene Therapy Center, Univ of North Carolina Chapel Hill, Chapel HIll, NC
  • Kenton Woodard
    Gene Therapy Center, Univ of North Carolina Chapel Hill, Chapel HIll, NC
  • Richard Samulski
    Gene Therapy Center, Univ of North Carolina Chapel Hill, Chapel HIll, NC
  • Footnotes
    Commercial Relationships Katharine Liang, None; Kenton Woodard, None; Richard Samulski, Asklepios BioPharmaceutical, Inc. (I)
  • Footnotes
    Support None
Investigative Ophthalmology & Visual Science June 2013, Vol.54, 1361. doi:
  • Views
  • Share
  • Tools
    • Alerts
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Katharine Liang, Kenton Woodard, Richard Samulski; AAV-mediated treatment of retinal degeneration in the Nrf2 knockout mouse. Invest. Ophthalmol. Vis. Sci. 2013;54(15):1361.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

  • Supplements

Purpose: Reactive oxygen species (ROS) are involved in a wide variety of aging processes, including retinal degeneration, making it an excellent therapeutic target. Under conditions of chronic oxidative stress, normal redox homeostasis is deregulated, resulting in ROS accumulation and subsequent cellular damage. One therapeutic strategy is overexpression of the transcription factor Nrf2, which drives downstream antioxidant gene expression. We applied novel AAV vectors to regulate oxidative stress in the Nrf2-deficient mouse, which exhibits an age-related retinal degeneration. Our research provides a targeted molecular approach to drive antioxidant gene expression, and offers a promising alternative to currently limited therapeutics for multifactorial diseases involving ROS deregulation.

Methods: We have engineered AAV2.5-CBh-Nrf2 vector using a chimeric capsid vector and promoter selected for retinal transduction via intravitreal injection. Functional efficacy of AAV-Nrf2 was evaluated using in vitro luciferase reporter and fluorescent ROS detection assays. Downstream gene activation was assessed by western blot. AAV-Nrf2 was delivered to via intravitreal injection during early stage retinopathy. Therapeutic efficacy was assessed using electroretinogram (ERG, Ganzfield Dome) and optical coherence tomography (OCT, Bioptigen).

Results: AAV2.5 combines the improved transduction properties of AAV1 with reduced antigenic cross-reactivity against antibodies directed at both parental serotypes while keeping the receptor binding properties of AAV2. Preliminary data supports the efficiency of AAV2.5 transgene delivery via intravitreal injection in the rodent retina. Preliminary ERG and OCT data suggests that AAV-Nrf2 is sufficient for rescue from age-related retinopathy seen in Nrf2-deficient mice. In vivo analysis is ongoing and update of Nrf2 expression is being monitored by both western and histological analysis.

Conclusions: AAV vector development combined with gene replacement offers a unique opportunity to optimize and test both efficient transgene delivery as well as potent therapeutic potential. Future studies to determine if a master regulator of a wide variety of antioxidant genes is promising or toxic to a therapeutic target will provide significant insight into future applications of this therapeutic approach.

Keywords: 538 gene transfer/gene therapy • 634 oxidation/oxidative or free radical damage • 695 retinal degenerations: cell biology  

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.